

Understanding myasthenia gravis

Myasthenia gravis (MG) is a chronic autoimmune disease characterized by fluctuating muscle weakness. In MG, the body's immune system attacks the connections between nerves and muscles, causing weakness and fatigue in muscles under your voluntary control.^{1,2}

Symptoms often emerge in the eyes:^{1,2}



Drooping eyelids



Blurred or double vision

In more advanced MG, symptoms progress into the face, throat and limbs:^{1,2}



Change in facial expression



Difficulty chewing or swallowing



Impaired speech



Weakness of arms, hands or legs



Difficulty breathing



Profound tiredness

MG is unpredictable, and often requires lifestyle modifications for people to engage in everyday activities.³


“With MG, you learn to embrace and plan for uncertainty. It’s a constant battle to figure out what your body needs.”

— Jonni, living with MG

Burden of MG Management

MG is a chronic illness with most people requiring lifelong therapy.⁴

Yet, current treatments do not fully address patient needs. Limitations include:⁵



Episodic or cyclical treatments



Prolonged time to onset of effect



Fear of disease flares



Safety and side effects



Invasive and / or burdensome routes of administration

A New Approach to Treatment⁶

At Immunovant, we're developing anti-FcRn technology that may reduce harmful IgG autoantibodies with tailored dosing, to help alleviate symptoms across disease stage and severity. Our aim is:



Rapid and deep IgG reduction to gain initial disease control



Maintenance dosing for sustainable control with potentially fewer side effects



Tailored dosing to address varying symptoms and disease fluctuations



Subcutaneous injection to enable self-administration at home

Learn more about our goal of reframing expectations in autoimmune disease at [Immunovant.com](https://immunovant.com)

IgG = immunoglobulin G

References:

1. National Institute of Neurological Disorders and Stroke. Myasthenia Gravis. Available at: <https://www.ninds.nih.gov/health-information/disorders/myasthenia-gravis>. Accessed October 16, 2023. 2. Myasthenia Gravis Foundation of America. Autoimmune Myasthenia Gravis brochure. Available at <https://myasthenia.org/MG-Education/Learn-More-About-MG-Treatments/MG-Brochures>. Accessed October 16, 2023. 3. MG Patient Quantitative Survey (n=50) Q: What is the extent of lifestyle modifications you make around your myasthenia gravis? 4. Drachman, D. Myasthenia Gravis. *Semin Neurol*. 2016 Oct; 36(5):419-424. 5. Market research data on file at Immunovant. 6. Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis; NCT05403541. Available at: <https://clinicaltrials.gov/ct2/show/NCT05403541?term=batoclimab&draw=2&rank=1>. Accessed October 16, 2023.